Yes, Juho mentioned that they ended up with something else, possibly Novartis.
The problem with drugs for specific mutations is that cancer cells will gradually find another pathway unless the attack is strong enough to prevent new cells from being selected for a bypass. Therefore, the body’s own immunity should also be activated, and that is what Bex and other immunomodulators aim for, regardless of mutations. Combinations.
In addition to Novartis, three other big pharma companies, Roche, AstraZeneca, and Lilly, are pursuing the same mutation. The risk decreases when you consider that others will also get their share, so we probably will too. When others share the same bread, the reward is also smaller. With Faron, it’s the other way around. Others are not publicly trying the same thing, which increases both risk and reward.